Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are male and were newly diagnosed with prostate cancer that had already spread to other parts of the body at the time of diagnosis (known as de novo metastatic hormone-sensitive prostate cancer)
- People who started a specific type of prostate cancer hormone therapy called an androgen receptor pathway inhibitor (ARPI) within 90 days before or after their diagnosis
- People who were 18 years of age or older when they started ARPI therapy
- People who also started hormone-suppressing therapy (ADT) and/or a chemotherapy drug called docetaxel within 90 days of starting ARPI therapy
- People who have at least 90 days of electronic medical record (health record) activity recorded before starting ARPI therapy
- People who have at least 90 days of electronic medical record activity after starting ARPI therapy, unless they passed away before that time
Who may not be able to join:
- People who have a history of any other type of cancer, apart from certain common skin cancers (non-melanoma skin cancer)
- People who used certain other cancer treatments — including PARP inhibitor drugs, chemotherapy drugs other than docetaxel, immunotherapy, or radioactive drug therapies — before starting ARPI therapy
- People whose medical records show any sign that their prostate cancer had become resistant to hormone treatment (castration-resistant) at any point before starting ARPI therapy, or within 90 days of their original diagnosis
- People who participated in another clinical trial at any point during the study period
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: (+)1-888-84 22937
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Describe baseline demographic of de novo mHSPC patients receiving darolutamide + ADT + docetaxel (triplet therapy): age; Describe baseline demographic of de novo mHSPC patients receiving darolutamide + ADT (doublet therapy): age; Describe baseline clinical characteristics of de novo mHSPC patients receiving darolutamide + ADT + docetaxel (triplet therapy): Concomitant Medication; Describe baseline clinical characteristics of de novo mHSPC patients receiving darolutamide + ADT (doublet therapy): Concomitant Medication; Describe baseline demographic of de novo mHSPC patients receiving darolutami...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.